PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$121.51
as of November 16, 2026 -
YTD RETURNS19.87%
as of November 16, 2026 -
Total Net Assets$1.09B
as of November 16, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 9.48 | 8.49 | 17.71 | 31.59 | 18.94 | 11.85 | 10.78 | 10.62 |
| PPH (Market Price) | 9.37 | 8.45 | 17.66 | 31.57 | 18.95 | 11.84 | 10.78 | 10.69 |
| MVIS US Listed Pharmaceutical 25 Index | 9.49 | 8.52 | 17.51 | 31.39 | 18.58 | 11.49 | 10.51 | 10.43 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | -3.28 | 0.50 | 7.51 | 23.60 | 13.35 | 10.67 | 8.69 | 10.00 |
| PPH (Market Price) | -3.19 | 0.67 | 7.58 | 23.72 | 13.37 | 10.65 | 8.70 | 10.09 |
| MVIS US Listed Pharmaceutical 25 Index | -3.26 | 0.55 | 7.32 | 23.42 | 13.00 | 10.31 | 8.44 | 9.81 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 11/16/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
23.05 |
246,115,526 |
|
MRK |
Merck & Co Inc |
11.92 |
127,279,228 |
|
NVO |
Novo Nordisk A/S |
5.53 |
59,069,046 |
|
MCK |
Mckesson Corp |
5.05 |
53,888,381 |
|
PFE |
Pfizer Inc |
4.70 |
50,192,504 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
4.60 |
49,111,051 |
|
COR |
Cencora Inc |
4.50 |
48,004,147 |
|
BMY |
Bristol-Myers Squibb Co |
4.42 |
47,204,296 |
|
GSK |
Gsk Plc |
4.22 |
45,074,253 |
|
ABBV |
Abbvie Inc |
3.68 |
39,247,904 |
|
AZN |
Astrazeneca Plc |
3.67 |
39,203,253 |
|
NVS |
Novartis Ag |
3.65 |
38,959,038 |
|
SNY |
Sanofi Sa/France |
3.54 |
37,754,991 |
|
HLN |
Haleon Plc |
3.40 |
36,264,624 |
|
JNJ |
Johnson & Johnson |
3.31 |
35,369,892 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
2.90 |
30,934,152 |
|
ZTS |
Zoetis Inc |
2.69 |
28,707,790 |
|
VTRS |
Viatris Inc |
1.58 |
16,880,784 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.23 |
13,139,156 |
|
ELAN |
Elanco Animal Health Inc |
0.53 |
5,637,769 |
|
AXSM |
Axsome Therapeutics Inc |
0.49 |
5,234,330 |
|
CORT |
Corcept Therapeutics Inc |
0.42 |
4,444,755 |
|
DFTX |
Definium Therapeutics Inc |
0.35 |
3,716,496 |
|
OGN |
Organon & Co |
0.26 |
2,815,070 |
|
PRGO |
Perrigo Co Plc |
0.11 |
1,123,119 |
|
-USD CASH- |
-- |
-0.00 |
-1,369 |
|
-- |
Other/Cash |
0.23 |
2,487,624 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 10/31/2026
-
Sector
% of Net Assets -
Health Care
99.90 -
Other/Cash
0.10
Country Weightings (%) as at 10/31/2026
-
Country
% of Net Assets -
United States
68.70 -
United Kingdom
11.27 -
Denmark
5.42 -
Israel
4.63 -
Switzerland
3.73 -
France
3.30 -
Japan
2.86 -
Other/Cash
0.10
Fees
Distributions
as of 11/16/2026
Quarterly
1.56%
1.19%
1.76%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency